SwanBio Therapeutics Raises $56 Million in Series B Financing

SwanBio Therapeutics, Philadelphia$56M raised by a PA-based gene therapy company in Series B funding.

TheRound, which brings total funding raised to date up to $133 Million, was led by Syncona LimitedAnd Mass General Brigham Ventures.

TheThe company plans to use the funds to continue to evolve into a fully integrated, integrated research and development organisation. Initial focus is on the clinical advancements of SBT101, which includes plans to dose patients. inA Phase1/2 trial by the end this year. For further progress in the pipeline, applying the learnings from SBT101 and other monogenic disorders as well as polygenic disorders.

SwanBio TherapeuticsGene Therapy Company that aims to offer life-changing treatments for people with inherited neurological conditions. TheA pipeline of gene therapies is being developed by the company, which can be administered intrathecally to target areas in both the central and peripheral nervous system. This approach has the potential to be applied broadly across three disease classifications – spastic paraplegias, monogenic neuropathies, and polygenic neuropathies. Its lead program is being advanced toward clinical development for the treatment of adrenomyeloneuropathy (AMN).

SBT101 is the first clinical-stage AAV-based gene therapy candidate for the treatment of adrenomyeloneuropathy (AMN). TheA new investigational drug has been developed to treat the disease-causing agent. ABCD1mutation inPeople living with AMN. ThisMutations in the function and structure of spinal cord cells, as well as other tissues, can cause nerve degeneration. This can lead to mobility loss. inAdulthood, incontinence or debilitating symptoms, and sexual dysfunction. PatientsSometimes, adrenal gland dysfunction can also occur. InThe FDA cleared the way in early 2022 SwanBio’s Investigational New DrugApplication for SBT101 granted Orphan DrugAnd Fast TrackSBT101 designations eyond the SBT101 SwanBioWe are developing a pipeline to deliver gene therapy candidates intrathecally to target patients. inBoth the central and peripheral nervous system, with an initial focus on spine-related disorders like AMN.



Leave a Comment